reference/16710232

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16710232

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	460
issn	0167-6997 1573-0646
issueIdentifier	5
pageRange	453-460
publicationName	Investigational New Drugs
startingPage	453
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5a0eb2fadabf1dffb4d70280b760adba
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_30998f1f23a84d32e875d03331ed8986 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_9ae821a089c3690ae5703553454c6260
bibliographicCitation	Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM. Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs. 2009 Oct;27(5):453–60. doi: 10.1007/s10637-008-9200-x. PMID: 19011760.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_48b113645d26951ca7e704cf4c400641 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_18b4270983c40d214d1894055e2e411b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee24bce34ac4dc3505ac25691a4249bb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7db666e3f32932c6c054d080a7730b32 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8429353f0c25bdfc600c2f85faeea7b5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a82b818bc3faab607d4f249cc326fea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_beb4d2c6e5ecac4d7b8b3c36d9e36317 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be99cf89b1011cf645e5024b91bef94e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d029a93846eaf1e8b873ffa8e2fa7c31 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a2e86a352bb421856f66f950247437d4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a30d34e4a1967222aa59b1f623420a4
date	2008-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/19011760 https://doi.org/10.1007/s10637-008-9200-x
isPartOf	https://portal.issn.org/resource/ISSN/1573-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372 https://portal.issn.org/resource/ISSN/0167-6997
language	English
source	https://www.crossref.org/ https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
discusses	http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0021267 http://id.nlm.nih.gov/mesh/M0479831
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4fb3b68e84149f91bcfd0102f95d3731 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71464628 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216326 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7732 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7947 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70683024 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_42cfbcd47747eec326f49bd492e9a41a http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7078

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID249267819 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129356432 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660

Total number of triples: 59.